DocMorris Reports Robust Revenue Growth in Q2 2026

Swiss-based healthcare company DocMorris AG announced a notable revenue increase of 15.2% in the second quarter of 2026, reaching CHF 309.7 million. The notable rise is driven by a 46% surge in prescription medicines (Rx) and an 80% growth in Digital Services. Active customer numbers rose by 1.1 million year-on-year, indicating significant expansion in new Rx customers.

CEO Walter Hess highlighted the sustainability of these gains, especially in the prescription sector, while CFO Daniel Wüest emphasized the effective operational and marketing strategies leading to this progress. In the German market segment, revenue climbed by 15.1%, underscoring the overall growth trend.

For the first half of 2026, DocMorris reports a 12.5% increase in external revenue, reaching CHF 627.8 million. The company foresees continued positive impacts from its business performance, coupled with its "AI-First" strategy announced in June.